esketamine + mometasone

**Esketamine + mometasone** is a hypothetical or unestablished combination drug consisting of **esketamine**, a non-competitive NMDA receptor antagonist approved for the treatment of treatment-resistant depression, and **mometasone**, a synthetic corticosteroid commonly used to treat inflammatory conditions such as allergic rhinitis and asthma. As of now, there is no evidence or record of a pharmaceutical product combining these two agents as a fixed-dose formulation or as a branded or clinical entity. **Esketamine** acts primarily by antagonizing the NMDA receptor, leading to rapid antidepressant effects in adults with major depressive disorder, particularly in those with treatment-resistant forms. **Mometasone** acts as a glucocorticoid receptor agonist, reducing inflammation via suppression of multiple inflammatory cytokines and mediators. No synergistic indication or studied clinical efficacy for the specific pairing of esketamine and mometasone exists in the clinical literature.